We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:TRIV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.87 | 0 | 00:00:00 |
February 5, 2016
VIA UPS AND EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | TriVascular Technologies, Inc. |
Withdrawal of Registration Statement on Form S-3
File No. 333-206854
Ladies and Gentlemen:
TriVascular Technologies, Inc., a Delaware corporation (the Company) hereby respectfully requests the withdrawal, effective as of the date hereof, of the Companys Registration Statement on Form S-3 (File No. 333-206854) filed with the Securities and Exchange Commission (the SEC) on September 10, 2015 together with all exhibits thereto (the Registration Statement). The Registration Statement was declared effective by the SEC on September 24, 2015.
On February 3, 2016, the Company completed the merger contemplated by the Agreement and Plan of Merger, dated as of October 26, 2015 (the Merger Agreement), by and among the Company, Endologix, Inc., a Delaware corporation (Endologix), and Teton Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Endologix (the Merger Sub). Pursuant to the terms of the Merger Agreement, the Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly-owned subsidiary of Endologix. As a result of the Merger, the Company has determined that it is in its best interest to withdraw the Registration Statement at this time.
In accordance with Rule 477 promulgated under the Securities Act of 1933, as amended, the Company hereby confirms that no securities were sold pursuant to the Registration Statement. The Company makes this application on the grounds that there is no longer a present intention to offer or sell securities under the Registration Statement.
If you have any questions regarding this application, please contact Michael Lawhead of Stradling Yocca Carlson & Rauth, P.C., our outside counsel, at (949) 725-4277.
Respectfully,
/s/ Vaseem Mahboob
Vaseem Mahboob
Chief Financial Officer
1 Year TRIVASCULAR TECHNOLOGIES, INC. Chart |
1 Month TRIVASCULAR TECHNOLOGIES, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions